Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2022 Dec 13;13:1097810. doi: 10.3389/fimmu.2022.1097810

Erratum: Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality

Frontiers Production Office1,*
PMCID: PMC9793744  PMID: 36582235

Due to a production error, there was a mistake in Figure 1 as published. The wrong figure was inserted as Figure 1 . The corrected Figure 1 appears below. The publisher apologizes for this mistake.

Figure 1.

Figure 1

Flow chart of the study. Study participants (n=100) were screened for participation during the first surge of the disease (March to May 2020) among 547 patients admitted for COVID either to the emergency department or to the ICU. Informed consent for participation was obtained in 49 COVID+ ICU+ patients, and in 24 COVID+ICU- patients, which were then admitted to the infectious disease department. In parallel, 11 participants were recruited in our staff (as healthy controls, COVID-ICU-), and so were 16 COVID-ICU+ patients that were admitted for non-COVID multiple organ failure requiring mechanical ventilation support.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES